Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Key facts
- Who runs it
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 425 people enrolled
- Started
- 4 Sept 2021
- Ended
- 27 Dec 2023
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Jaktinib
- placebo
- Record updated
- 14 March 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- participants voluntarily sign the informed consent form (ICF)
- Age ≥ 18 years and <65 years, either male or female
- Clinical presentation compatible with alopecia areata with a current episode lasting not exceeding ≤8 years
- At least 50% scalp hair loss
- Willing to comply with the study visits and requirements of the study protocol
Who cannot take part
- participants has taken a JAK inhibitor prior to randomization
- participants who are unsuitable to the trial, as identified by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
The 3 groups in the trial
- Jaktinib 50mg BIDTreatment being tested
Participants received Jaktinib 50mg tablets, orally, twice daily (BID) for up to 24 weeks.
Treatment: Jaktinib
- Jaktinib 75mg BIDTreatment being tested
Participants received Jaktinib 75mg tablets, orally, twice daily (BID) for up to 24 weeks.
Treatment: Jaktinib
- placeboPlacebo, for comparison
Participants received Jaktinib matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
- Record updated
- 14 March 2025